Krystal Biotech, Inc.
HealthcareNASDAQ:KRYS · NASDAQ Global Market
-$3.58 today
Vol 0.29M · Avg 0.28M
Income Statement
Follow revenue through to earnings
Review sales, margins, expenses, and profit trends to see what is actually driving reported earnings over time.
Earnings Waterfall
Revenue to Net Income
Key Ratios
Analysis
$417.3M of revenue converted into $225.0M of net income for the selected period. Gross margin is 92.8% and net margin is 54.3%, showing how much revenue survives after costs and taxes. EPS is $7.48, tying the income statement back to per-share earnings.
Income Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $389.1M +33.9% | $290.5M +473.0% | $50.7M | $0 | $0 | $809.6M | $921.6M | $731.2M |
| Cost of Revenue | $28.8M +43.4% | $20.1M +548.4% | $3.1M | $0 | $0 | $725.6M | $804.0M | $882.4M |
| Gross Profit | $360.4M +33.2% | $270.5M +468.1% | $47.6M | $0 | $0 | $8.9B | $7.6B | $6.2B |
| Gross Margin | 92.6% -0.5pp | 93.1% -0.8pp | 93.9% | — | — | 9.8% | 28.9% | 38.3% |
| Research & Development | $58.0M +8.3% | $53.6M +15.4% | $46.4M +9.3% | $42.5M +52.3% | $27.9M | $983.2M | $1.3B | $490.4M |
| Selling, General & Admin | $146.7M +29.1% | $113.7M +15.5% | $98.4M +26.6% | $77.7M +92.5% | $40.4M | $620.6M | $923.0M | -$1.5B |
| Operating Expenses | $199.1M -2.8% | $204.8M +30.1% | $157.3M +8.4% | $145.2M +112.7% | $68.3M | $5.3B | $7.0B | $8.7B |
| Depreciation & Amortization | $6.6M -2.4% | $6.7M +13.6% | $5.9M +74.6% | $3.4M +83.1% | $1.8M | $374.2M | $1.2B | $631.8M |
| EBITDA | $196.0M +78.3% | $109.9M +220.4% | -$91.3M +21.8% | -$116.8M -76.4% | -$66.2M | -$15.2B | $6.8B | $9.3B |
| EBITDA Margin | 50.4% +12.5pp | 37.8% +217.9pp | -180.1% | — | — | 5.6% | 46.3% | 42.0% |
| Operating Income | $161.3M +145.5% | $65.7M +159.9% | -$109.7M +24.4% | -$145.2M -112.7% | -$68.3M | $12.3B | $14.0B | -$15.7B |
| Operating Margin | 41.5% +18.8pp | 22.6% +239.0pp | -216.4% | — | — | 16.6% | 24.1% | 22.0% |
| Interest Income | $28.2M -5.0% | $29.7M +31.1% | $22.6M +333.3% | $5.2M +2550.3% | $197.0K | -$1.5B | -$1.6B | $405.0M |
| Interest Expense | $0 | $0 | $0 | $0 -100.0% | $1.5M | $1.1B | $1.0B | $1.2B |
| Other Income / Expenses | $28.2M -5.0% | $29.7M -75.8% | $122.6M +2248.7% | $5.2M +503.2% | -$1.3M | -$1.5B | $1.4B | $1.2B |
| Income Before Tax | $189.5M +98.7% | $95.4M +639.4% | $12.9M +109.2% | -$140.0M -101.2% | -$69.6M | $3.3B | $4.9B | $3.6B |
| Pre-Tax Margin | 48.7% +15.9pp | 32.8% +7.4pp | 25.4% | — | — | 20.8% | 18.7% | 26.2% |
| Income Tax Expense | -$15.4M -347.9% | $6.2M +215.4% | $2.0M | $0 | $0 | $1.3B | -$1.6B | $745.2M |
| Net Income | $204.8M +129.7% | $89.2M +715.6% | $10.9M +107.8% | -$140.0M -101.2% | -$69.6M | $4.9B | $4.8B | $4.7B |
| Net Margin | 52.6% +21.9pp | 30.7% +9.1pp | 21.6% | — | — | 12.4% | 17.5% | 22.5% |
| EPS (Basic) | $7 +126.9% | $3 +680.0% | $0 +107.3% | -$5 -75.4% | -$3 | $400.8M | $703.2M | $1.3B |
| EPS (Diluted) | $7 +128.0% | $3 +669.2% | $0 +107.1% | -$5 -75.4% | -$3 | $766.2M | $609.4M | $452.6M |
| Weighted Avg Shares | $28.9M +1.2% | $28.6M +5.3% | $27.2M +6.5% | $25.5M +14.8% | $22.2M | $757.8M | $925.8M | $1.1B |
| Weighted Avg Shares (Diluted) | $30.0M +0.7% | $29.7M +7.2% | $27.8M +8.9% | $25.5M +14.8% | $22.2M | $1.2B | $924.4M | $678.0M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Arrowhead Pharmaceuticals, Inc.
NASDAQ:ARWR
$10.50B
TG Therapeutics, Inc.
NASDAQ:TGTX
$7.58B
Metsera, Inc.
MTSR
$7.43B
Alkermes plc
NASDAQ:ALKS
$7.38B
Protagonist Therapeutics, Inc.
NASDAQ:PTGX
$7.06B
Vaxcyte, Inc.
NASDAQ:PCVX
$6.85B
Arcellx, Inc.
ACLX
$6.73B
PTC Therapeutics, Inc.
NASDAQ:PTCT
$6.23B
Teleflex Incorporated
NYSE:TFX
$5.78B
CRISPR Therapeutics AG
NASDAQ:CRSP
$4.80B
SEC Filings
Recent regulatory filings
No filings found.
How much revenue does KRYS generate?
Krystal Biotech, Inc. (KRYS) reported $389.13M of revenue in fiscal 2025.
Is KRYS profitable?
Krystal Biotech, Inc. (KRYS) reported $204.83M of net income, with a net margin of 52.6%.
Explore More
Continue the stock analysis
Jump to another research area for this company.